Compositions, Devices, and Methods for Intranasal Delivery of Dry Powder Epinephrine
Summary
Belhaven BioPharma Inc. has filed USPTO patent application US20260108459A1 for intranasal dry powder epinephrine compositions. The application was filed on June 19, 2025, with inventors Scott Lyman and Brian Taubenheim. The compositions include epinephrine with citric acid as a stabilizing agent and are intended for treating anaphylaxis, bronchospasms, respiratory impairment, organophosphate poisoning, and major adverse cardiac events.
“Such intranasal compositions as described herein are useful in the treatment of health conditions which threaten the central nervous system (CNS) and impede the actions of alpha and beta-adrenergic receptors.”
About this source
USPTO classification A61M covers devices that introduce or withdraw fluids from the body: infusion pumps, catheters, syringes, inhalers, wound drainage, dialysis equipment, and fluid-handling microfluidics. Every newly published application in A61M lands in this feed, around 205 a month. Applications publish 18 months after filing. Watch this if you compete in infusion therapy or drug delivery, file freedom-to-operate analyses for medical device startups, scout acquisition targets in cardiovascular or respiratory devices, or track hospital R&D arms that are quietly patenting clinical innovations.
What changed
Belhaven BioPharma Inc. has filed a patent application with the USPTO for intranasal dry powder epinephrine compositions. The application covers compositions containing epinephrine or a pharmaceutically acceptable salt, a stabilizing agent (citric acid or salt thereof), and a carrier, configured for intranasal delivery. The compositions are intended for treating conditions affecting the central nervous system that impede alpha and beta-adrenergic receptors, including anaphylaxis, bronchospasms, respiratory impairment, organophosphate poisoning, and major adverse cardiac events.
Pharmaceutical companies developing epinephrine delivery systems or anaphylaxis treatments should monitor this application for potential freedom-to-operate implications. While patent applications do not immediately affect market access, the disclosed formulation and delivery method could influence future product development strategies in the epinephrine and anaphylaxis treatment space.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOSITIONS, DEVICES, AND METHODS FOR INTRANASAL DELIVERY OF DRY POWDER EPINEPHRINE
Application US20260108459A1 Kind: A1 Apr 23, 2026
Assignee
Belhaven BioPharma Inc.
Inventors
Scott Lyman, Brian Taubenheim
Abstract
Intranasal dry powder epinephrine compositions are described herein. The compositions include epinephrine or a pharmaceutically acceptable salt thereof, as well as a stabilizing agent and a carrier. The stabilizing agent is operable to include citric acid, or a pharmaceutically acceptable salt derived therefrom. Such intranasal compositions as described herein are useful in the treatment of health conditions which threaten the central nervous system (CNS) and impede the actions of alpha and beta-adrenergic receptors. Such health conditions include anaphylaxis, bronchospasms, respiratory impairment, organophosphate poisoning, and major adverse cardiac events (MACE).
CPC Classifications
A61K 9/0075 A61K 9/14 A61M 11/001 A61M 15/08
Filing Date
2025-06-19
Application No.
19243323
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Medical Devices (A61M)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Medical Devices (A61M) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.